- |||||||||| teropavimab (GS-5423) / Rockefeller University, Gilead, 10-1074-LS-J / IAVI, Rockefeller University, 3BNC117-LS-J / Rockefeller University, IAVI
New P1 trial, Immunomodulating: PAUSE: Pausing Antiretroviral Treatment Under Structured Evaluation (clinicaltrials.gov) - Sep 11, 2023
P1, N=48, Not yet recruiting,
- |||||||||| 10-1074-LS-J / IAVI, Rockefeller University, 3BNC117-LS-J / Rockefeller University, IAVI
Trial completion date, Trial primary completion date: Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults (clinicaltrials.gov) - Mar 10, 2023
P1/2, N=225, Active, not recruiting,
Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Mar 2022 --> Sep 2023
- |||||||||| 10-1074-LS-J / IAVI, Rockefeller University, 3BNC117-LS-J / Rockefeller University, IAVI
Enrollment closed, Trial completion date, Trial primary completion date: Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults (clinicaltrials.gov) - Jun 14, 2022
P1/2, N=225, Active, not recruiting,
Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Mar 2022 --> Sep 2023 Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- |||||||||| 10-1074-LS-J / IAVI, Rockefeller University, 3BNC117-LS-J / Rockefeller University, IAVI
Enrollment open, Trial initiation date: Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults (clinicaltrials.gov) - Jan 30, 2020
P1/2, N=225, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 Not yet recruiting --> Recruiting | Initiation date: Dec 2019 --> Jan 2019
|
